Medigen Vaccine Valuation
| 6547 Stock | TWD 47.95 0.35 0.74% |
At this time, the firm appears to be overvalued. Medigen Vaccine Biologics secures a last-minute Real Value of NT$42.68 per share. The latest price of the firm is NT$47.95. Our model forecasts the value of Medigen Vaccine Biologics from analyzing the firm fundamentals such as Return On Equity of 0.0662, current valuation of 24.78 B, and Profit Margin of 0.13 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Medigen Vaccine's price fluctuation is very steady at this time. Calculation of the real value of Medigen Vaccine Biologics is based on 3 months time horizon. Increasing Medigen Vaccine's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Medigen stock is determined by what a typical buyer is willing to pay for full or partial control of Medigen Vaccine Biologics. Since Medigen Vaccine is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Medigen Stock. However, Medigen Vaccine's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 47.95 | Real 42.68 | Hype 47.95 |
The intrinsic value of Medigen Vaccine's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Medigen Vaccine's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Medigen Vaccine Biologics helps investors to forecast how Medigen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Medigen Vaccine more accurately as focusing exclusively on Medigen Vaccine's fundamentals will not take into account other important factors: Medigen Vaccine Total Value Analysis
Medigen Vaccine Biologics is presently anticipated to have takeover price of 24.78 B with market capitalization of 23.36 B, debt of 286.54 M, and cash on hands of 2.12 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Medigen Vaccine fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.78 B | 23.36 B | 286.54 M | 2.12 B |
Medigen Vaccine Investor Information
About 28.0% of the company shares are owned by insiders or employees . The book value of Medigen Vaccine was presently reported as 17.52. The company had not issued any dividends in recent years. Medigen Vaccine Biologics had 1482:1000 split on the 3rd of August 2022. Based on the measurements of operating efficiency obtained from Medigen Vaccine's historical financial statements, Medigen Vaccine Biologics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Medigen Vaccine Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Medigen Vaccine has an asset utilization ratio of 61.92 percent. This indicates that the Company is making NT$0.62 for each dollar of assets. An increasing asset utilization means that Medigen Vaccine Biologics is more efficient with each dollar of assets it utilizes for everyday operations.Medigen Vaccine Ownership Allocation
Medigen Vaccine Biologics maintains a total of 327.2 Million outstanding shares. Medigen Vaccine Biologics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Medigen Vaccine Profitability Analysis
The company reported the revenue of 3.28 B. Net Income was 1.41 B with profit before overhead, payroll, taxes, and interest of 2.31 B.About Medigen Vaccine Valuation
Our relative valuation model uses a comparative analysis of Medigen Vaccine. We calculate exposure to Medigen Vaccine's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Medigen Vaccine's related companies.Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp. MEDIGEN VACCINE operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
8 Steps to conduct Medigen Vaccine's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Medigen Vaccine's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Medigen Vaccine's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Medigen Vaccine's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Medigen Vaccine's revenue streams: Identify Medigen Vaccine's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Medigen Vaccine's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Medigen Vaccine's growth potential: Evaluate Medigen Vaccine's management, business model, and growth potential.
- Determine Medigen Vaccine's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Medigen Vaccine's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Medigen Stock Analysis
When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.